BMO Capital Markets Issues Positive Forecast for Protagonist Therapeutics (NASDAQ:PTGX) Stock Price
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) had its target price boosted by equities researchers at BMO Capital Markets from $62.00 to $72.00 in a report released on Tuesday, Marketbeat reports. The firm currently has an “outperform” rating on the stock. BMO Capital Markets’ price target suggests a potential upside of 24.89% from the stock’s […]
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) had its target price boosted by equities researchers at BMO Capital Markets from $62.00 to $72.00 in a report released on Tuesday, Marketbeat reports. The firm currently has an “outperform” rating on the stock. BMO Capital Markets’ price target suggests a potential upside of 24.89% from the stock’s […]
